respiratori
virus
caus
signific
morbid
mortal
immunocompromis
popul
stem
cell
transplant
solid
organ
transplant
patient
virus
caus
respiratori
tract
infect
approv
therapi
mani
virus
therapeut
option
articl
describ
novel
agent
develop
treatment
option
sever
respiratori
virus
respiratori
virus
caus
wide
rang
upper
lower
respiratori
tract
infect
urti
lrti
gener
popul
immunocompromis
popul
particularli
undergo
chemotherapi
malign
solid
organ
hematopoeit
stem
cell
transplant
patient
viral
respiratori
infect
caus
high
rate
morbid
mortal
antivir
therapi
exist
provid
benefit
pathogen
new
therapi
investig
howev
remain
limit
data
efficaci
mani
new
agent
immunocompromis
popul
review
describ
current
publish
literatur
regard
novel
antivir
agent
use
respiratori
virus
immunocompromis
host
influenza
singlestrand
segment
rna
viru
remain
one
challeng
respiratori
viral
infect
immunocompromis
popul
mainstay
treatment
season
influenza
pandem
influenza
b
continu
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
although
inhibitor
amantadin
rimantadin
approv
influenza
widespread
resist
present
preclud
use
latter
class
agent
one
limit
use
nai
emerg
resist
occur
frequent
immunocompromis
popul
peramivir
intraven
iv
nai
studi
treatment
sever
influenza
infect
peramivir
use
emerg
emerg
investig
new
drug
eind
program
treat
seriou
ill
caus
pandem
influenza
one
review
patient
differ
state
patient
treat
eind
earli
phase
pandem
transplant
patient
patient
solid
organ
transplant
hematopoiet
stem
cell
transplant
hsct
addit
patient
eind
cohort
system
corticosteroid
overal
author
classifi
patient
receiv
peramivir
immunocompromis
children
patient
studi
sever
ill
respiratori
failur
two
adult
patient
die
recov
one
child
recov
die
peramivir
therapi
review
peramivir
use
emerg
use
author
california
author
identifi
immunosuppress
patient
total
defin
immunosuppress
drug
cancer
chemotherapi
leukemia
system
lupu
erythematosu
transplant
immunosuppress
condit
five
patient
live
baselin
characterist
predict
mortal
cohort
final
sever
case
report
describ
treatment
peramivir
one
case
pediatr
renal
transplant
patient
sever
oseltamivirresist
influenza
recov
follow
peramivir
therapi
howev
patient
also
aggress
critic
care
support
reduct
immunosuppress
hsct
patient
peramivir
associ
recoveri
sever
pandem
influenza
peramivir
use
concurr
lymphocyt
recoveri
oseltamivir
use
preced
tripl
combin
antivir
therapi
oseltamivir
oral
ribavirin
oral
amantadin
well
inhal
ribavirin
intraven
immunoglobulin
detect
oseltamivir
resist
mutat
addit
role
peramivir
manag
patient
document
resist
oseltamivir
call
question
allogeniec
hsct
patient
oseltamivirresist
viru
due
neuraminidas
mutat
viru
replic
continu
despit
peramivir
therapi
overal
limit
data
allow
conclus
efficaci
peramivir
immunocompromis
popul
inhal
zanamivir
anoth
nai
approv
influenza
therapi
limit
data
inhal
zanamivir
transplant
popul
toler
outcom
suggest
reason
option
although
studi
need
investig
iv
zanamivir
avail
compassionateus
basi
set
failur
antivir
contraind
inhal
zanamivir
part
clinic
trial
failur
absorb
oseltamivir
develop
oseltamivirresist
specif
mutat
report
indic
usag
retrospect
studi
iv
zanamivir
critic
ill
patient
pandem
influenza
alreadi
receiv
least
day
oseltamivir
prior
iv
zanamivir
immunocompromis
seven
patient
develop
acut
respiratori
distress
syndrom
patient
die
sever
case
report
pediatr
immunocompromis
host
includ
hsct
leukemia
liver
transplant
appear
literatur
predominantli
oseltamivirresist
pandem
influenza
viral
isol
surviv
result
mix
patient
report
decreas
viral
load
evalu
polymerasechain
reaction
pcr
threshold
cycl
valu
remain
case
report
relat
pediatr
transplant
patient
mix
surviv
result
data
iv
zanamivir
immunocompromis
popul
remain
scant
may
benefit
use
oseltamivirresist
influenza
infect
laninamivir
octano
longact
inhal
nai
approv
japan
octob
given
persist
airway
singl
dose
gener
use
studi
date
laninamivir
octano
shown
efficaci
season
influenza
oseltamivirresist
influenza
influenza
virus
immunocompet
subject
postmarket
studi
laninamivir
octano
patient
classifi
diseas
accompani
reduct
immun
function
group
categor
respond
treatment
fever
resolut
relief
influenza
symptom
present
littl
data
efficaci
laninamivir
octano
immunocompromis
person
sialidas
fusion
protein
anoth
novel
agent
activ
influenza
parainfluenza
virus
mechan
action
cleav
termin
sialic
acid
linkag
host
cell
reduc
bind
infect
viru
vitro
vivo
studi
suggest
activ
oseltamivirresist
strain
influenza
current
studi
anim
model
one
phase
ii
trial
phase
ii
studi
patient
infect
season
influenza
pandem
influenza
influenza
b
associ
statist
signific
reduct
viral
load
day
otherwis
gener
healthi
patient
one
death
occur
femal
patient
previous
undiagnos
hiv
infect
expir
respiratori
failur
sever
pneumonia
h
influenza
aureu
isol
sputum
cultur
overal
evalu
influenza
infect
necessari
particularli
immunocompromis
popul
see
data
manag
parainfluenza
viru
respiratori
syncyti
viru
rsv
envelop
nonseg
rna
viru
paramyxoviru
famili
caus
urti
lrti
immunocompromis
host
rsv
infect
link
signific
morbid
mortal
popul
progress
lrti
associ
increas
mortal
hsct
rsv
epidemiolog
associ
develop
bronchiol
obliteran
syndrom
bo
adult
lung
transplant
recipi
variou
therapi
assess
impact
diseas
progress
morbid
mortal
sever
emerg
therapeut
investig
ribavirin
guanosin
analog
activ
rna
dna
virus
avail
oral
intraven
aerosol
administr
discov
year
ago
major
research
clinic
use
center
inhal
aerosol
form
drug
emerg
data
use
oral
ribavirin
manag
rsv
ribavirin
oral
absorb
without
food
halflif
day
administ
time
extens
accumul
tissu
activ
influenza
measl
west
nile
viru
rsv
virus
oral
ribavirin
becam
avail
pelaez
describ
use
conjunct
steroid
adult
lung
transplant
recipi
find
oral
therapi
less
costli
aerosol
intervent
directli
compar
placebo
formul
ribavirin
addit
comparison
outcom
lung
transplant
recipi
receiv
oral
n
inhal
n
ribavirin
conjunct
steroid
ivig
perform
singl
center
signific
differ
report
surviv
bo
developmentprogress
month
postinfect
cohort
studi
assess
concentr
oral
ribavirin
lung
fluid
transplant
patient
conduct
despit
limit
data
efficaci
clear
rsv
infect
solid
organ
transplant
sot
ribavirin
especi
aerosol
form
addit
evalu
conjunct
therapi
includ
steroid
ivig
palivizumab
see
remain
standard
part
mani
local
treatment
protocol
palivizumab
motavizumab
antibodi
rsv
fusion
protein
current
palivizumab
approv
prophylaxi
rsv
infect
select
group
prematur
infant
children
year
age
uncorrect
cyanot
congenit
heart
diseas
chronic
lung
diseas
motavizumab
time
potent
palivizumab
random
studi
motavizumab
exhibit
increas
skin
reaction
advers
event
similar
clinic
outcom
palivizumab
longer
halflif
may
allow
less
frequent
dose
neither
motavizumab
studi
immunocompromis
host
date
palivizumab
assess
hsct
lung
transplant
recipi
largest
studi
palivizumab
evalu
two
group
hsct
recipi
first
group
hsct
patient
without
rsv
receiv
palivizumab
note
serum
halflif
day
addit
hsct
patient
rsv
receiv
palivizumab
addit
aerosol
ribavirin
palivizumab
clear
rapidli
rsvinfect
group
halflif
day
patient
urti
recov
without
progress
lrti
patient
lrti
surviv
past
studi
period
addit
palivizumab
given
hsct
patient
along
infect
prevent
measur
includ
patient
cohort
visitor
screen
hand
hygien
success
administ
prophylact
nosocomi
outbreak
rsv
final
palivizumab
use
part
multidrug
regimen
includ
inhal
ribavirin
steroid
ivig
lung
transplant
recipi
rsv
forc
expiratori
volum
one
second
treatment
similar
baselin
howev
progress
bo
impact
rsv
therapi
patient
highergrad
bo
infect
rapid
declin
followup
period
compar
without
bo
infect
small
interf
rna
enter
cell
target
rsvspecif
viral
mrna
interfer
viral
replic
two
random
placebocontrol
trial
aerosol
agent
perform
lung
transplant
recipi
studi
perform
hsct
date
zamora
colleagu
report
lung
transplant
recipi
confirm
rsv
receiv
n
placebo
n
day
cumul
total
daili
symptom
score
p
new
progress
bo
rate
day
p
lower
recipi
simon
colleagu
studi
addit
lung
transplant
recipi
rsv
receiv
day
placebo
longer
followup
period
day
patient
lower
rate
new
progress
bo
compar
placebo
vs
p
treatment
effect
seen
regardless
ribavirin
coadministr
novel
rsvspecif
antivir
previous
report
novel
antirsv
activ
subtyp
b
phase
safeti
toler
studi
healthi
control
studi
plan
hsct
recipi
rsv
clinicaltrialsgov
inform
result
yet
avail
literatur
two
fusion
inhibitor
act
block
rsv
fusion
protein
investig
tmc
evalu
mous
monkey
model
show
vivo
antirsv
activ
given
via
dri
powder
aerosol
success
test
phase
studi
safeti
toler
healthi
asthmat
adult
neither
agent
evalu
use
immunocompromis
host
date
nanobodi
also
bind
rsv
fusion
protein
f
allow
attach
viru
cell
fusion
cell
preclud
infect
novel
antibodi
aros
discoveri
dromedari
deliv
directli
lung
via
aerosol
studi
healthi
male
volunt
phase
random
placebocontrol
protocol
evalu
dose
safeti
toler
pharmacokinet
agent
test
immunocompromis
host
parainfluenza
viru
piv
singlestrand
envelop
rna
viru
describ
caus
sever
infect
lead
increas
morbid
mortal
immunocompromis
popul
previous
publish
report
describ
infect
stem
cell
transplant
lung
transplant
patient
sever
publish
case
report
describ
treatment
piv
type
lrti
immunocompromis
popul
whose
mechan
describ
two
patient
unilater
lung
transplant
sever
lower
respiratori
tract
diseas
receiv
day
therapi
symptom
improv
patient
soon
treatment
start
reduct
viral
load
occur
case
patient
discharg
recoveri
ill
side
effect
includ
mild
elev
alkalin
phosphatas
resolv
complet
therapi
hsct
two
case
describ
autolog
hsct
recipi
histori
multipl
myeloma
allogen
hsct
recipi
recov
day
therapi
respect
also
variabl
reduct
viral
load
therapi
howev
patient
experienc
relaps
infect
primari
diseas
point
therapi
pursu
human
rhinoviru
hrhv
member
picornaviru
genera
serotyp
three
differ
speci
b
recent
character
c
spectrum
diseas
immunocompromis
popul
also
rang
mild
sever
treatment
hrhv
remain
support
sinc
activ
agent
current
commerci
avail
new
oral
drug
vapendavir
biota
pharmaceut
inc
melbourn
australia
bind
viral
capsid
inhibitinterfer
receptor
bind
subsequ
prevent
infect
develop
phase
random
doubleblind
placebocontrol
studi
asthmat
hrhv
infect
show
greater
mean
reduct
asthma
score
higher
even
peak
expiratori
flow
vapendavir
group
versu
placebo
addit
investig
immunocompromis
host
need
adenoviru
adv
doublestrand
nonenvelop
dna
viru
serotyp
seven
speci
ag
identifi
adv
caus
dissemin
local
diseas
pneumonia
immunocompet
immunosuppress
popul
nucleosid
analog
ribavirin
ganciclovir
cidofovir
shown
vitro
activ
adv
howev
cidofovir
recommend
treatment
adv
infect
recent
lipidconjug
oral
form
cidofovir
chimerix
durham
nc
studi
hsct
sot
first
eind
program
treat
sever
adv
infect
children
adult
enrol
hsct
sot
surviv
studi
complet
death
dissemin
infect
local
infect
attribut
adv
diseas
other
expir
due
caus
surviv
local
lung
diseas
report
florescu
report
patient
receiv
salvag
therapi
dissemin
adv
avail
analysi
hsct
sot
sever
combin
immunodefici
cid
respiratori
diseas
diagnos
patient
patient
expir
secondari
adv
pneumonia
nine
patient
experienc
decreas
plasma
viral
load
end
treatment
followup
period
patient
respond
therapi
decreas
viral
load
surviv
improv
median
day
versu
day
p
compar
nonrespond
welltoler
explor
therapeut
option
adv
infect
immunocompromis
popul
envelop
rna
viru
human
coronaviru
hcov
famili
coronavirida
gener
caus
infect
winter
respiratori
viral
season
usual
mild
immunocompet
host
hcov
infect
immunosuppress
popul
lead
signific
lower
respiratori
tract
diseas
furthermor
emerg
hcov
sever
acut
respiratori
syndromeassoci
hcov
sarscov
recent
identifi
novel
coronaviru
ncov
mer
prompt
concern
develop
therapeut
famili
virus
effect
antivir
agent
current
lack
discoveri
vitro
evalu
novel
hcov
therapeut
underway
investig
entri
inhibitor
human
monoclon
antibodi
proteosom
inhibitor
even
scorpion
venom
peptid
hcov
treatment
remain
support
current
antivir
armamentarium
respiratori
viral
infect
asid
influenza
therapi
limit
result
option
impact
associ
morbid
mortal
ill
immunocompromis
host
new
drug
current
develop
could
signific
impact
treat
infect
drug
laninamivir
octano
avail
certain
market
other
access
eind
mechan
unit
state
still
antivir
earli
clinic
preclin
investig
stage
addit
investig
need
particularli
immunocompromis
host
expand
option
effect
therapi
respiratori
viral
infect
